Itron’s Expanded Cellular‑Mesh UtilityIQ Platform Might Change The Case For Investing In Itron (ITRI)

• Itron, Inc. recently expanded its UtilityIQ Application Suite to support new Cellular 500G and 500W modules for gas and water meters in the US, enabling utilities to combine cellular and mesh connectivity over its Gen6 network platform.
• A particularly important angle is that the upgraded, multi-transport headend and interoperable cellular modules let utilities mix vendors and deployment models without overhauling existing infrastructure.
• We’ll now examine how this enhanced cellular‑mesh interoperability within UtilityIQ could influence Itron’s longer-term grid modernization and utility IoT investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Itron Investment Narrative Recap

To own Itron, you need to believe utilities will keep investing in grid and water infrastructure that increasingly depends on interoperable communications and software. The UtilityIQ cellular‑mesh upgrade reinforces that story but does not materially change the key near term swing factors, which remain the timing of large AMI project awards and the risk that regulatory or customer budget delays push deployments out.

The recent US$700 million convertible zero coupon notes due 2032 are particularly relevant here, as they add financial flexibility that can support continued investment in platforms like Gen6 and UtilityIQ. For investors focused on execution, the question is whether this balance sheet capacity helps Itron keep advancing its Outcomes and IoT offerings without stretching its risk profile.

Yet beneath the technology upside, investors should be aware that prolonged regulatory and customer delays could...

Read the full narrative on Itron (it's free!)

Itron's narrative projects $2.8 billion revenue and $388.8 million earnings by 2028. This requires 5.2% yearly revenue growth and about a $118.9 million earnings increase from $269.9 million today.

Uncover how Itron's forecasts yield a $138.22 fair value, a 47% upside to its current price.

Exploring Other Perspectives

Four members of the Simply Wall St Community currently estimate Itron’s fair value between US$72.87 and US$166.89, highlighting very different expectations. Against that spread, the reliance on timely approval and rollout of large, backlog driven projects could meaningfully influence how those views play out over time, so it is worth comparing several of these opinions before forming your own.

Explore 4 other fair value estimates on Itron - why the stock might be worth as much as 78% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Itron research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Itron research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Itron's overall financial health at a glance.

Ready For A Different Approach?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Uncover the next big thing with 32 elite penny stocks that balance risk and reward.
• We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com